Canada - English - Health Canada

teva canada limited - febuxostat (febuxostat hemihydrate) - tablet - 80mg - febuxostat (febuxostat hemihydrate) 80mg - antigout agents

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - febuxostat - film-coated tablet - 80 milligram(s) - preparations inhibiting uric acid production; febuxostat

Ireland - English - HPRA (Health Products Regulatory Authority)

rowex ltd - febuxostat - film-coated tablet - 120 milligram(s) - preparations inhibiting uric acid production; febuxostat

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - febuxostat - film-coated tablet - 80 milligram(s) - preparations inhibiting uric acid production; febuxostat

Ireland - English - HPRA (Health Products Regulatory Authority)

clonmel healthcare ltd - febuxostat - film-coated tablet - 120 milligram(s) - preparations inhibiting uric acid production; febuxostat

United States - English - NLM (National Library of Medicine)

msn laboratories private limited - febuxostat (unii: 101v0r1n2e) (febuxostat - unii:101v0r1n2e) - febuxostat tablets are xanthine oxidase (xo) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. limitations of use: febuxostat tablets are not recommended for the treatment of asymptomatic hyperuricemia.   febuxostat is contraindicated in patients being treated with azathioprine or mercaptopurine [see drug interactions (7)] . risk summary limited available data with febuxostat use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. no adverse developmental effects were observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal exposures up to 40 and 51 times, respectively, the exposure at the maximum recommended human dose (mrhd). no adve

United States - English - NLM (National Library of Medicine)

novadoz pharmaceuticals llc - febuxostat (unii: 101v0r1n2e) (febuxostat - unii:101v0r1n2e) - febuxostat tablets are xanthine oxidase (xo) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. limitations of use: febuxostat tablets are not recommended for the treatment of asymptomatic hyperuricemia.   febuxostat is contraindicated in patients being treated with azathioprine or mercaptopurine [see drug interactions (7)] . risk summary limited available data with febuxostat use in pregnant women are insufficient to inform a drug associated risk of adverse developmental outcomes. no adverse developmental effects were observed in embryo-fetal development studies with oral administration of febuxostat to pregnant rats and rabbits during organogenesis at doses that produced maternal exposures up to 40 and 51 times, respectively, the exposure at the maximum recommended human dose (mrhd). no adve

United States - English - NLM (National Library of Medicine)

nucare pharmaceuticals,inc. - febuxostat (unii: 101v0r1n2e) (febuxostat - unii:101v0r1n2e) - febuxostat tablets are xanthine oxidase (xo) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. febuxostat tablets are not recommended for the treatment of asymptomatic hyperuricemia.   febuxostat tablets are xanthine oxidase (xo) inhibitor indicated for the chronic management of hyperuricemia in adult patients with gout who have an inadequate response to a maximally titrated dose of allopurinol, who are intolerant to allopurinol, or for whom treatment with allopurinol is not advisable. for the safe and effective use of allopurinol, see allopurinol prescribing information. limitations of use: febuxostat tablets are not recommended for the treatment of asymptomatic hyperuricemia.   febuxostat is contraindicated in patients being treated with azathioprine or merca

Ireland - English - HPRA (Health Products Regulatory Authority)

rowa pharmaceuticals limited - febuxostat - film-coated tablet - 120 milligram(s) - preparations inhibiting uric acid production; febuxostat

Ireland - English - HPRA (Health Products Regulatory Authority)

rowa pharmaceuticals limited - febuxostat - film-coated tablet - 80 milligram(s) - preparations inhibiting uric acid production; febuxostat